ChemicalBook > CAS DataBase List > Beraprost

Beraprost

Product Name
Beraprost
CAS No.
88430-50-6
Chemical Name
Beraprost
Synonyms
Domer;ML 1229;BERAPROST;Befaprost;MDL 201229;Beraprostum;Unii-35E3njj4o6;Beraprostum [inn-latin];88475-69-8 (Hydrochloride salt);JWH-018 Impurity 5(N-Pentyl-5-carboxylic Acid)
CBNumber
CB8746083
Molecular Formula
C24H30O5
Formula Weight
398.49
MOL File
88430-50-6.mol
More
Less

Beraprost Property

Boiling point:
572.1±50.0 °C(Predicted)
Density 
1.254±0.06 g/cm3(Predicted)
pka
4.76±0.10(Predicted)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
API0001669
Product name
BERAPROST
Purity
95.00%
Packaging
5MG
Price
$1842.23
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
API0001669
Product name
BERAPROST
Purity
95.00%
Packaging
10MG
Price
$2728.69
Updated
2021/12/16
AK Scientific
Product number
K578
Product name
Beraprost
Packaging
10mg
Price
$4505
Updated
2021/12/16
AHH
Product number
MT-47782
Product name
Beraprost
Purity
98%
Packaging
1g
Price
$330
Updated
2021/12/16
More
Less

Beraprost Chemical Properties,Usage,Production

Uses

Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral).

Mechanism of action

Beraprost is a chemically stable, oral form of prostacyclin that is readily absorbed from GI tract. Like natural prostacyclin, beraprost dilates blood vessels, prevents platelet aggregation, and prevents proliferation of smooth muscle cells surrounding blood vessels. It may be an important treatment for early stage PVD and for early stage pulmonary hypertension. Intermittent oral doses of beraprost, however, do not seem to provide the consistent blood levels necessary to treat the advanced stages of pulmonary hypertension.

Clinical Use

Beraprost is an oral formulation of a prostacyclin analog for the treatment of early stage pulmonary hypertension as well as early stage PVD.

Side effects

Adverse effects include headache, flushing, jaw pain, and diarrhea.

Enzyme inhibitor

This orally active epoprostenol analogue (FW = 398.50 g/mol; CAS 88475- 69-8; Soluble to 25 mM in DMSO), also named TRA-418 and 2,3,3a,8b- tetrahydro-2-hydroxy-1- (3-hydroxy-4-methyl-1-octen-6-yn-1-yl) -1H- cyclopenta[b]benzofuran-5-butanoic acid, is a potent agonist for the Prostacyclin Receptor, a member of the G-protein coupled receptor family. Prostacyclin, the major product of cyclooxygenase in macrovascular endothelium, elicits a potent vasodilation and inhibition of platelet aggregation through binding to this receptor. Beraprost potently inhibits ADP-induced platelet aggregation (pIC50 = 8.26) and P-selectin expression in vitro (pIC50 = 8.56). It also increases vasodilation and reduces pulmonary hypertension in vivo. TRA-418 inhibited platelet GPIIb/IIIa activation as well as induction of P-selectin expression by adenosine 5'-diphosphate, Thrombin Receptor Agonist Peptide 1-6 (Ser-Phe-Leu-Leu-Arg-Asn-NH2), and U-46619 in the presence of epinephrine. TRA-418 also inhibits platelet aggregation induced by those platelet-stimulants in Ca2+-chelating anticoagulant, citrate and in nonchelating anticoagulant, d-phenylalanyl-l- prolyl-l-arginyl-chloromethyl ketone (PPACK). The TP-receptor antagonist SQ-29548 inhibited only U-46619+epinephrine-induced GPIIb/IIIa activation, P-selectin expression, and platelet aggregation. The IP-receptor agonist beraprost sodium inhibited platelet activation. Beraprost also inhibited platelet aggregation induced by platelet stimulants we tested in citrate and in PPACK. The GPIIb/IIIa inhibitor abciximab blocked GPIIb/IIIa activation and platelet aggregation. However, abciximab showed slight inhibitory effects on P-selectin expression. TRA-418 is more advantageous as an antiplatelet agent than TP-receptor antagonists or IP- receptor agonists separately used. TRA-418 showed a different inhibitory profile from abciximab in the effects on P-selectin expression.

Beraprost Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Beraprost Suppliers

LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38632
Advantage
58
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
2A PharmaChem USA
Tel
--
Fax
--
Email
sales@2apharmachem.com
Country
United States
ProdList
6137
Advantage
39
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6718
Advantage
47
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65

88430-50-6, BeraprostRelated Search:


  • 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3A,8B-tetrahydro-1H-cyclopenta(B)benzofuran-5-butanoic acid
  • 88475-69-8 (Hydrochloride salt)
  • Beraprostum
  • Beraprostum [inn-latin]
  • Unii-35E3njj4o6
  • 2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid
  • BERAPROST
  • 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-
  • MDL 201229
  • ML 1229
  • 2,3,3α,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid
  • Befaprost
  • Domer
  • 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl]butanoic acid
  • 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-
  • JWH-018 Impurity 5(N-Pentyl-5-carboxylic Acid)
  • 88430-50-6